COVID-19 Vaccines Interim Analysis: Unanswered Questions
Abstract
It will be one year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created havoc and mayhem in form of coronavirus disease 2019 (COVID-19) pandemic. Many potential vaccines candidates are identified and are currently in different phases of clinical trial. The international regulatory authority has given emergency approval of two vaccines, Pfizer and BioNTech and Moderna. The Phase 3 trial of both these vaccines are still in progress and there are scattered reports of adverse effects including allergic reaction among vaccinated health care workers. The safety profile of these vaccines requires long term follow up of patients before one can assure its efficacy and clinical effectiveness.
References
The challenges for COVID vaccination efforts: Nature. 2020; 587: 522.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-
candidate-against . 2020.
https://www.modernatx.com/sites/default/files/content_documents/mRNA-1273-Update-11-16-20-
Final.pdf . 2020.
https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html. 2020.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open-label, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396: 887-97.
Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post- licensure studies. Vaccine. 2013; 31: 5634-42.
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KR, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases. 2020.
US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19: Guidance for industry. Docket FDA-2020-D-1137, FDA, 2020.
World Health Organization. WHO target product profiles for COVID-19 vaccines.
Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. The Lancet Public Health. 2020; 5: e444-51.
Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divall P, et al. The impact of ethnicity on clinical outcomes in COVID- 19: A systematic review. E Clinical Medicine. 2020.
Docherty AB, Harrison EM, Green CA et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterization protocol: prospective observational cohort study. BMJ. 2020; 369: m1985.
Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020.
An Antidote to the Age of Anxiety: Alan Watts on Happiness and How to Live with Presence https://www.brainpickings.org/2014/01/06/alan-watts- wisdom-of-insecurity-1/
